Celyad - We care, we cure About Products Cardiology Oncology Medical Devices Therapeutic areas Cardiology Oncology Clinical trials Investors Financial reports Shareholder meetings Regulated information Corporate Governance News Events Press Jobs Contact us FR About Products Cardiology Oncology Medical Devices Therapeutic areas Cardiology Oncology Clinical trials Investors Financial reports Shareholder meetings Regulated information Corporate Governance News Events Press Jobs Contact us FR Celyad reports First Half 2015 financial results and operational progress Read the press release Translating breakthrough research into transformative treatments Get introduced to Celyad Celyad seeks to address high unmet medical needs Read more about the therapeutic areas we focus on Discover our product candidates in oncology and cardiology Discover our products • • • • About Celyad Celyad – previously Cardio3 BioSciences – is a biopharmaceutical company focused on translating breakthrough cell-based research into innovative therapeutics to improve the outcome of severe diseases. The Company is currently developing clinical stage cell therapies in cardiology and oncology, two healthcare segments with high unmet medical needs. More about the company Celyad announces the appointment of Dr. Frederic Lehmann as Vice President Immuno-Oncology Corporate press releases | 15 September, 2015 Celyad announces the appointment of Dr. Debasish Roychowdhury as independent director Financial press releases | 04 September, 2015 Celyad announces commercial license agreement for C-Cure® in Greater China Corporate press releases | 31 August, 2015 CEO & Chairman message Play Unique therapies for transformational cures Celyad's lead product candidate in cardiovascular disease is C-Cure®, an autologous cell therapy based on the Company's Cardiopoiesis technology platform. The Cardiopoiesis platform consists of mesenchymal cells engineered to improve their reparative capabilities for the treatment of congestive heart failure. In oncology, the company is developing CAR T-cell therapies for the treatment of various different cancers. The lead immuno-oncology product NKG2D CAR T-cell is an autologous T-cell transduced with a NKG2D receptor present on Natural Killer (NK) cells that binds to numerous types of cancer cells, including blood cancers and solid tumors. Read more Celyad - We care, we cure Sign up to our newsletter Stay informed about the latest news ! Sign up Follow us Youtube Twitter Linkedin Glossary Press Jobs Newsletter Contact us Disclaimer